Cargando…

Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment

Background: Melphalan was poorly available in mainland China. The aim of this study is to explore the dose-adjusted busulfan/cyclophosphamide (BU/CY) as an alternative regimen in auto stem cell transplantation (ASCT) for multiple myeloma (MM). Methods: A total of 105 newly diagnosed MM patients unde...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Shiyuan, Zhai, Yingying, Yan, Lingzhi, Shi, Xiaolan, Shang, Jingjing, Wu, Depei, Fu, Chengcheng, Jin, Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10573400/ https://www.ncbi.nlm.nih.gov/pubmed/37834886 http://dx.doi.org/10.3390/jcm12196239

Ejemplares similares

Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Rodriguez, Tulio E., et al.
Publicado: (2016)

Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
por: Byun, Ja Min, et al.
Publicado: (2018)

Conditioning regimen using busulfan plus melphalan in hematopoietic stem cell transplantation: can this conditioning regimen be used in autologous or allogeneic transplantation for acute leukemia?
por: Lemoli, Roberto M., et al.
Publicado: (2011)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Busulfan-cyclophosphamide versus cyclophosphamide-busulfan as conditioning regimen before allogeneic hematopoietic cell transplantation: a prospective randomized trial
por: Seydoux, Claire, et al.
Publicado: (2020)

Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma
por: Park, Songyi, et al.
Publicado: (2021)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m(2) conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis
por: Gao, Fei, et al.
Publicado: (2021)

Phase 2 Clinical Trial of High-Dose Gemcitabine/Busulfan/Melphalan for Autologous Stem-Cell Transplantation in Relapsed/Refractory Myeloma: Matched-Pair Comparison with Melphalan
por: Nieto, Yago, et al.
Publicado: (2017)

Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation
por: Mehdizadeh, Mahshid, et al.
Publicado: (2021)

Thiotepa, Busulfan, Cyclophosphamide: Effective but Toxic Conditioning Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation in Central Nervous System Lymphoma
por: Delphine, Lebon, et al.
Publicado: (2023)

Busulfan and melphalan as conditioning regimen for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia in first complete remission
por: Bueno, Nadjanara Dorna, et al.
Publicado: (2011)

Is there any difference between busulfan-cyclophosphamide and cyclophosphamide-busulfan in patients underwent allogeneic transplantation?
por: Bahçecioğlu, Ömer Faruk, et al.
Publicado: (2021)

Safety and efficacy of a modified busulfan/cyclophosphamide conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation in acute myeloid leukemia
por: Shi, Yuan-Yuan, et al.
Publicado: (2023)

P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
por: Chen, S., et al.
Publicado: (2022)

Mitoxantrone-melphalan conditioning regimen for autologous stem cell transplantation in relapsed/refractory lymphoma
por: OKAY, Müfide, et al.
Publicado: (2019)

Comparison of Melphalan Combined with Treosulfan or Busulfan as High-Dose Chemotherapy before Autologous Stem Cell Transplantation in AML
por: Gurevich, Ekaterina, et al.
Publicado: (2022)

Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma
por: Srour, Samer A., et al.
Publicado: (2021)

Allogeneic stem cell transplant for multiple myeloma & myelofibrosis with split-dose busulfan, fludarabine & cyclophosphamide
por: Trunk, Andrew D., et al.
Publicado: (2023)

Busulfan and thiotepa as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-1801 study)
por: Song, Ga-Young, et al.
Publicado: (2022)

The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning
por: Ursu, Sorana G., et al.
Publicado: (2023)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study
por: Popat, Uday R., et al.
Publicado: (2022)

PB2193: IS HYPERHYDRATION NECESSARY FOR HIGH DOSE MELPHALAN CONDITIONING REGIMEN IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION?
por: Mora Argumánez, M., et al.
Publicado: (2022)

P1298: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR ALLOGENEIC-HSCT IN REFRACTORY/RELAPSED OR PERSISTENT MRD POSITIVITY AML PATIENTS
por: Jiang, Erlie, et al.
Publicado: (2023)

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
por: Zeng, Qiang, et al.
Publicado: (2023)

A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma
por: Radhakrishnan, Sabarinath V., et al.
Publicado: (2019)

Busulfan, Melphalan, and Etoposide (BuME) Showed an Equivalent Effect to Busulfan, Cyclophosphamide, and Etoposide (BuCE) as Conditioning Therapy for Autologous Stem Cell Transplantation in Patients with Relapsed or High-Risk Non-Hodgkin’s Lymphoma: A Multicenter Randomized Phase II Study by the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Kyoung Ha, et al.
Publicado: (2023)

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study
por: Liu, Hui, et al.
Publicado: (2013)

Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen
por: Young, Patricia A., et al.
Publicado: (2020)

Assessing the Efficacy of Alkylating Agent Regimens in the Treatment of Infantile Malignant Osteopetrosis: Cyclophosphamide, Busulfan, or Thiotepa
por: Wagh, Himanshu, et al.
Publicado: (2022)

Comparable Outcomes using Propylene Glycol-Free Melphalan for Autologous Stem Cell Transplantation in Multiple Myeloma
por: Miller, Kevin C., et al.
Publicado: (2018)

BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
por: Wu, Ran, et al.
Publicado: (2023)

Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide
por: Lee, Ji Hyun, et al.
Publicado: (2010)

Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma
por: Shimizu, Kazuyuki, et al.
Publicado: (1990)

Single-Agent High-Dose Melphalan as Conditioning Regimen in Autologous Hematopoietic Stem Cell Transplantation for Hodgkin's Lymphoma: Safety, and Long-Term Efficacy
por: Al Hashmi, Hani, et al.
Publicado: (2018)

The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.
por: Hinchliffe, M., et al.
Publicado: (1983)

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Pharmacokinetic‐Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High‐Dose Melphalan for Autologous Stem Cell Transplant
por: Cho, Yu Kyoung, et al.
Publicado: (2018)

Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation
por: Martino, Massimo, et al.
Publicado: (2023)

A case report: high dose melphalan as a conditioning regimen for multiple myeloma induces sinus arrest
por: Ma, Liang-Liang, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d84lmhbo5s6nor7i7nkurhvrcn